Cellusion Inc. is a regenerative medicine startup founded by three professors in Keio university school of medicine, department of ophthalmology in Japan. The Headquarters locates in Tokyo. Cellusion has several unique technologies including highly efficient direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. Cellusion‘s lead program coded as CLS001 is targeting Bullous Keratopathy which is a major corneal endothelial disease currently treated only by corneal transplantation. The investigator-initiated clinical study of CLS001 is about to start in Keio university hospital soon. Besides, Cellusion has several pipelines focusing on not only ophthalmologic diseases, but also beyond ophthalmologic diseases.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):